Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens

Leukemia and Lymphoma

Volumn 45, Issue 1, 2004, Pages 61-65

  Sahara, Naohi ^a   Takeshita, Akihiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD56; Heterogeneity; Multiple myeloma; Prognosis; Surface markers

Indexed keywords

BENCE JONES PROTEIN; CD20 ANTIGEN; CD28 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; SYNDECAN 1; VERY LATE ACTIVATION ANTIGEN 5;

ANTIGEN EXPRESSION; B LYMPHOCYTE; BLAST CELL; CANCER CELL; CELL STRUCTURE; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; KIDNEY FAILURE; LYMPHOCYTE DIFFERENTIATION; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA;

ANTIGENS, CD56; HUMANS; INTEGRINS; MULTIPLE MYELOMA; NEURAL CELL ADHESION MOLECULES; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; TUMOR MARKERS, BIOLOGICAL;

EID: 0842301527     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000149377     Document Type: Review

References (43)

1. Bataille, R., Boccadoro, M., Klein, B., Durie, B. and Pileri, A. (1992) "C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system", Blood, 80, 733-737.
2. Greipp, P.R., Lust, J.A., O'Fallon, M., Katzmann, J.A., Witzig, T.E. and Kyle, R.A. (1993) "Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma", Blood, 81, 3382-3387.
3. Shaughnessy, J., Tian, E., Sawyer, J., McCoy, J., Tricot, G., Jacobson, J., et al. (2003) "Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II", British Journal of Haematology, 120, 44-52.
4. Durie, B.G. and Grogan, T.M. (1985) "CALLA-positive myeloma: an aggressive subtype with poor survival", Blood, 66, 229-232.
5. San Miguel, J.F., Gonzalez, M., Gascon, A., Moro, M.J., Hernandez, J.M., Ortega, F., et al. (1991) "Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease", British Journal of Haematology, 77, 185-190.
6. Ruiz-Arguelles, G.J. and San Miguel, J.F. (1994) "Cell surface markers in multiple myeloma", Mayo Clinic Proceedings, 69, 684-690.
7. Rawstron, A.C., Owen, R.G., Davies, F.E., Johnson, R.J., Jones, R.A., Richards, S.J., et al. (1997) "Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage", British Journal of Haematology, 97, 46-55.
8. Trowbridge, I.S. and Thomas, M.L. (1994) "CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development", Annual Review of Immunology, 12, 85-116.
9. Kishihara, K., Penninger, J., Wallace, V.A., Kundig, T.M., Kawai, K., Wakeham, A., et al. (1993) "Normal B lymphocyte development but impaired T cell maturation in CD45-exon 6 protein tyrosine phosphatase-deficient mice", Cell, 74, 143-156.
10. Thomas, M.L. (1995) "Positive and negative regulation of leukocyte activation by protein tyrosine phosphatases", Seminars in Immunology, 7, 279-288.
11. Cyster, J.G., Healy, J.I., Kishihara, K., Mak, T.W., Thomas, M.L. and Goodnow, C.C. (1996) "Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45", Nature, 381, 325-328.
12. Streuli, M., Hall, L.R., Saga, Y., Schlossman, S.F. and Saito, H. (1987) "Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens", Journal of Experimental Medicine, 166, 1548-1566.
13. Jensen, G.S., Mant, M.J., Belch, A.J., Berenson, J.R., Ruether, B.A. and Pilarski, L.M. (1991) "Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells", Blood, 78, 711-719.
14. Jensen, G.S., Poppema, S., Mant, M.J. and Pilarski, L.M. (1989) "Transition in CD45 isoform expression during differentiation of normal and abnormal B cells", International Immunology, 1, 229-235.
15. Menke, D.M., Horny, H.P., Griesser, H., Atkinson, E.J., Kaiserling, E. and Kyle, R.A. (1998) "Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1)", Journal of Clinical Pathology, 51, 432-437.
16. Pellat-Deceunynck, C., Barille, S., Puthier, D., Rapp, M.J., Harousseau, J.L., Bataille, R., et al. (1995) "Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization", Cancer Research, 55, 3647-3653.
17. Linsley, P.S. and Ledbetter, JA. (1993) "The role of the CD28 receptor during T cell responses to antigen", Annual Review of Immunology, 11, 191-212.
18. Rudd, C.E., Janssen, O., Cai, Y.C., Da Silva, A.J., Raab, M. and Prasad, K.V. (1994) "Two-step TCR CD3-CD4, and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases", Immunology Today, 15, 225-234.
19. June, C.H., Bluestone, J.A., Nadler, L.M. and Thompson, C.B. (1994) "The B7 and CD28 receptor families", Immunology Today, 15, 321-337.
20. Guinan, E.C., Gribben, J.G., Boussiotis, V.A., Freeman, G.J. and Nadler, L.M. (1994) "Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity", Blood, 84, 3261-3282.
21. Kozbor, D., Moretta, A., Messner, H.A., Moretta, L. and Croce, C.M. (1987) "Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells", Journal of Immunology, 138, 4128-4132.
22. Robillard, N., Jego, G., Pellat-Deceurynck, C., Pineau, D., Puthier, D., Mellerin, M.P., et al. (1998) "CD28, a marker associated with tumoral expansion in multiple myeloma", Clinical Cancer Research, 4, 1521-1526.
23. Kyle, R.A. (1994) "Why better prognosis factors for myeloma are needed", Blood, 87, 1713-1716.
24. Ahsmann, E.J., Benschop, R.J., De Gruyl, T.D., Faber, J.A., Lokhorst, H.M. and Bloem, A.C. (1993) "A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma", Clinical and Experimental Immunology, 93, 456-463.
25. Kawano, M.M., Huang, N., Harada, H., Harada, Y., Sakai, A., Tanaka, H., et al. (1993) "Identification of immature and mature myeloma cells in the bone marrow of human myelomas", Blood, 82, 564-570.
26. Kawano, M.M., Mahmoud, M.S., Huang, N., Lisukov, I.A., Mihara, K., Tsujimoto, T., et al. (1995) "High proportions of VLA-5-immature myeloma cells correlated well with poor response to treatment in multiple myeloma", British Journal of Haematology, 91, 860-864.
27. Rawstron, A.C., Barrans, S.L., Blythe, D., English, A., Richards, S.J., Fenton, J.A., et al. (2001) "In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression", British Journal of Haematology, 113, 794-802.
28. Walsh, F.S. and Doherty, P. (1997) "Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance", Annual Review of Cell and Developmental Biology, 13, 425-456.
29. Van Camp, B., Durie, B.G., Spier, C., De Waele, M., Van Riet, I., Vela, E., et al. (1990) "Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19 ", Blood, 76, 377-382.
30. Pellat-Deceunynck, C., Barille, S., Jego, G., Puthier, D., Robillard, N., Pineau, D., et al. (1998) "The absence of CD56 (NCAM on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma", Leukemia, 12, 1977-1982.
31. Rawstron, A.C., Barrans, S., Blythe, D., Davies, F., English, A., Pratt, G., et al. (1999) "Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression", British Journal of Haematology, 104, 138-143.
32. Mathew, P., Ahmann, G.J., Witzig, T.E., Roche, P.C., Kyle, R.A. and Greipp, P.R. (1995) "Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?", British Journal of Haematology, 90, 459-461.
33. Sahara, N., Takeshita, A., Shigeno, K., Fujisawa, S., Takeshita, K., Naito, K., et al. (2002) "Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma", British Journal of Haematology, 117, 882-885.
34. Harada, H., Kawano, M.M., Huang, N., Harada, Y., Iwato, K., Tanabe, O., et al. (1993) "Phenotypic difference of normal plasma cells from mature myeloma cells", Blood, 81, 2658-2663.
35. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., et al. (1988) "Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas", Nature, 32, 83-85.
36. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., et al. (1989) "Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6", Blood, 73, 517-526.
37. Kishimoto, T., Akira, S., Narazaki, M. and Taga, T. (1995) "Interleukin-6 family of cytokines and gp130", Blood, 86, 1243-1254.
38. Heinrich, P.C., Behrmann, I., Muller-Newen, G., Schaper, F. and Graeve, L. (1998) "Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway", Biochemical Journal, 334, 297-314.
39. Rawstron, A.C., Fenton, J.A., Ashcroft, J., English, A., Jones, R.A., Richards, S.J., et al. (2000) "The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells", Blood, 96, 3880-3886.
40. Barille, S., Thabard, W., Robillard, N., Moreau, P., Pineau, D., Harousseau, J.L., et al. (1999) "CD130 rather than CD126 expression is associated with disease activity in multiple myeloma", British Journal of Haematology, 106, 532-535.
41. Kim, I., Uchiyama, H., Chauhan, D. and Anderson, K.C. (1994) "Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines", British Journal of Haematology, 87, 483-493.
42. Huang, N., Kawano, M.M., Mahmoud, M.S., Mihara, K., Tsujimoto, T., Niwa, O., et al. (1995) "Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells", Blood, 85, 3704-3712.
43. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A., et al. (1996) "Multiple myeloma cell adhesion-induced interleukin - 6 expression in bone marrow stromal cells involves activation of NF-kappa B", Blood, 87, 1104-1112.